Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2015 (2015), Article ID 975028, 7 pages
http://dx.doi.org/10.1155/2015/975028
Research Article

Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East

1Weill Cornell Medical College in Qatar and Hamad General Hospital, Doha, Qatar
2Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait
3Rheumatic Disease Unit, Alamiri Hospital, Kuwait City, Kuwait
4Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
5Rheumatology Ward, Loghman Hakim University Hospital, Shahid Beheshti University of Medical Sciences, Tehran 14155 6153, Iran

Received 12 January 2015; Revised 21 April 2015; Accepted 30 April 2015

Academic Editor: Tim Jansen

Copyright © 2015 Mohammed Hammoudeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Mohammed Hammoudeh, Adel Al Awadhi, Eman Haji Hasan, Maassoumeh Akhlaghi, Arman Ahmadzadeh, and Bahar Sadeghi Abdollahi, “Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East,” International Journal of Rheumatology, vol. 2015, Article ID 975028, 7 pages, 2015. doi:10.1155/2015/975028